Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRI Bio insider option grant: Director Camilla V. Simpson was granted a stock option on 09/18/2025 to buy 23,605 shares of GRI Bio common stock at a $1.93 exercise price. Of the option, 17,621 shares vested immediately on the grant date and 5,984 shares will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The option expires on 09/18/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/22/2025.
GRI Bio insider option grant: Director Camilla V. Simpson was granted a stock option on 09/18/2025 to buy 23,605 shares of GRI Bio common stock at a $1.93 exercise price. Of the option, 17,621 shares vested immediately on the grant date and 5,984 shares will vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. The option expires on 09/18/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/22/2025.
GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.
GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.
GRI Bio, Inc. (GRI) reporting a Section 16 Form 4 for Vipin Chaturvedi, Chief Scientific Officer, showing a stock option grant on 09/18/2025. The reported derivative is a stock option with an exercise price of $1.93 covering 43,222 shares of common stock. Of those options, 29,923 vested in full on the grant date and 13,299 will vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The options are exercisable through 09/18/2035. The Form 4 lists 43,222 underlying shares beneficially owned following the transaction and indicates direct ownership. The filing is signed by Leanne Kelly, Attorney-in-Fact, dated 09/22/2025.
GRI Bio director Roelof Rongen reported a stock option grant that became partially vested on 09/18/2025. The filing shows options to purchase 23,605 shares of common stock at an exercise price of $1.93 per share, exercisable through 09/18/2035. Following the grant, Mr. Rongen beneficially owns 23,605 option shares directly. Of those options, 17,621 vested immediately on the grant date and 5,984 will vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of the grant date.
The Form 4 was filed as a single reporting person filing and bears a signature dated 09/22/2025 by an attorney-in-fact.
GRI Bio director Roelof Rongen reported a stock option grant that became partially vested on 09/18/2025. The filing shows options to purchase 23,605 shares of common stock at an exercise price of $1.93 per share, exercisable through 09/18/2035. Following the grant, Mr. Rongen beneficially owns 23,605 option shares directly. Of those options, 17,621 vested immediately on the grant date and 5,984 will vest in four substantially equal quarterly installments, with the option fully vested on the first anniversary of the grant date.
The Form 4 was filed as a single reporting person filing and bears a signature dated 09/22/2025 by an attorney-in-fact.
GRI Bio, Inc. (GRI) reporting person Walter Marc Hertz, identified as Director and Chief Executive Officer, was granted a stock option award on 09/18/2025 covering 103,067 shares with an exercise price of $1.93 per share. The award is exercisable through 09/18/2035. Under the grant, 76,469 options vested in full on the grant date and the remaining 26,598 options vest in 12 substantially equal quarterly installments, completing on the third anniversary of the grant. The Form 4 was signed by an attorney-in-fact on 09/22/2025. The filing shows direct beneficial ownership of the options and does not include additional cash compensation or other transaction types.
GRI Bio, Inc. (GRI) reporting person Walter Marc Hertz, identified as Director and Chief Executive Officer, was granted a stock option award on 09/18/2025 covering 103,067 shares with an exercise price of $1.93 per share. The award is exercisable through 09/18/2035. Under the grant, 76,469 options vested in full on the grant date and the remaining 26,598 options vest in 12 substantially equal quarterly installments, completing on the third anniversary of the grant. The Form 4 was signed by an attorney-in-fact on 09/22/2025. The filing shows direct beneficial ownership of the options and does not include additional cash compensation or other transaction types.
Walter Marc Hertz, identified as Chief Executive Officer and a director of GRI Bio, Inc. (GRI), reported on Form 4 a transaction dated 08/26/2025 involving stock options. He acquired 26,688 shares of common stock by exercising options with an exercise price of $1.41 per share. Of the options, 17,828 vested in full on the grant date and 8,860 will vest in 12 substantially equal quarterly installments, with the option fully vested on the third anniversary of the grant date. Following the transaction, Mr. Hertz beneficially owns 26,688 shares directly. The filing is signed by an attorney-in-fact, Leanne Kelly.
David Leslie Szekeres, a director of GRI Bio, Inc. (GRI), reported receipt of a stock option award covering 10,276 shares with an exercise price of $1.41 per share. The option was granted on 08/26/2025, has an expiration date in 2035, and 6,933 of the option shares vested immediately while the remaining 3,343 shares vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. Following the grant, the reporting person beneficially owns 10,276 option shares on a direct basis.
GRI Bio, Inc. director David Charles Baker received a stock option grant on 08/26/2025 allowing purchase of 5,994 shares of common stock at an exercise price of $1.41 per share. Of the total, 4,044 options vested immediately on the grant date; the remaining 1,950 options vest in four substantially equal quarterly installments and will be fully vested on the one-year anniversary of the grant. The options expire on 08/26/2035. Following the grant, Mr. Baker directly beneficially owns 5,994 underlying shares from the option award.
Roelof Rongen, a director of GRI Bio, Inc. (GRI), was granted a stock option on 08/26/2025 covering 5,994 shares with an exercise price of $1.41. The option has an expiration date of 08/26/2035 and the form reports 5,994 shares beneficially owned by the reporting person following the transaction. Of the options granted, 4,044 vested in full on the grant date and 1,950 will vest in four substantially equal quarterly installments, completing vesting on the first anniversary of the grant. The Form 4 was signed by an attorney-in-fact, Leanne Kelly, on 08/26/2025.
Vipin Chaturvedi, Chief Scientific Officer of GRI Bio, Inc. (GRI), reported receipt of a stock option award dated 08/26/2025 covering 11,854 options to purchase common stock at an exercise price of $1.41 per share. Following the reported transaction, he beneficially owns 11,854 options directly. The grant vests in two parts: 7,424 options vested in full on the grant date, while 4,430 options will vest in 12 substantially equal quarterly installments and become fully vested on the third anniversary of the grant. The option expiration date is 08/26/2035. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Camilla V. Simpson, a director of GRI Bio, acquired a stock option covering 5,994 shares of the issuer's common stock with an exercise price of $1.41. The option grant is exercisable beginning 08/26/2025 and expires 08/26/2035. Of the 5,994 underlying shares, 4,044 vested immediately and 1,950 vest in four substantially equal quarterly installments so the option is fully vested on the first anniversary of the grant. Following the reported transaction, Ms. Simpson beneficially owns 5,994 shares and holds them in a direct ownership form. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact.